A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulins in Insulin Naïve Patients Initiating Insulin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 705 participants.

Also called NCT02967224

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 705 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02967224
  • EudraCT 2015-001831-18
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil, France, Germany, Ireland, Romania, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02967224. Randomized; no masking; primary purpose treatment. Start 2015-11-05 (registry gives no type); primary completion 2017-10-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
Acronym
Reach-Control
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin glargine (U300)
Intervention (Drug)
insulin glargine (U100)
Intervention (Drug)
NPH insulin
Intervention (Drug)
insulin detemir
Intervention (Drug)
insulin degludec
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02967224
Content hash
6f663d16c527964ba54b3579a731be4427680f52f36920ecb70801fc3c070fd3